Guardian Pharmacy Services, Inc.

NYSE•GRDN

CEO: Mr. Fred P. Burke

Sector: Healthcare

Industry: Medical - Distribution

Listing Date: 2016-04-21

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

Contact Information

300 Galleria Parkway SE, Suite 800, Atlanta, GA, 30339, United States

404-810-0089

guardianpharmacy.com

Market Cap

$2.49B

P/E (TTM)

50.5

30.5

Dividend Yield

52W High

$39.53

52W Low

$19.17

52W Range

99%

Rank30Top 19.5%

5.1

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Average • 5.1 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$397.62M+0.00%

4-Quarter Trend

EPS

$0.33+0.00%

4-Quarter Trend

FCF

$30.37M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth Strong Revenue reached $1.45B USD in 2025, marking a 17.9% increase over 2024 results, driven by organic growth.

Operating Income Turnaround Switched to $72.7M USD operating income in 2025 from prior year loss of $62.9M K, showing profitability.

Adjusted EBITDA Improvement Adjusted EBITDA reached $115.1M USD, showing strong growth of 26.8% compared to the previous year's $90.8M K.

High ALF Adoption Rate Resident adoption rate reached 89% at ALFs served by year-end December 31, 2025, demonstrating key operational strength.

Risk Factors

Intense Market Competition Competition from national/local pharmacies may erode profit margins and adversely affect operating results and cash flow.

Healthcare Cost Pressures Continuing government efforts to lower drug prices via reforms like IRA may adversely impact profitability and reimbursement rates.

Labor Shortages Harm Growth Inability to attract/retain pharmacists and staff could harm growth strategy implementation and increase operating costs.

Cybersecurity Incident Risk Past ransomware attack highlights risk; future security incidents could disrupt operations and expose us to regulatory penalties.

Outlook

Growth Strategy Pillars Core strategy centers on organic growth via new residents and increased adoption, supplemented by strategic M&A activity.

Technology Investment Focus Continued investment in automation, data analytics (Guardian Compass/Shield), and IT infrastructure planned for efficiency gains.

Ongoing Geographic Expansion Expansion through acquiring compatible pharmacies or developing greenfield start-ups in existing and underserved regional markets.

New Predictive Programs Actively developing new predictive tools, including Falls Risk Management and Disease State Management services for LTCFs.

Peer Comparison

Revenue (TTM)

QDEL

$2.73B

-1.9%

TDOC

$2.53B

-1.5%

$1.91B

-4.9%

Gross Margin (Latest Quarter)

NUVB

99.0%

+182.9pp

NVCR

75.8%

-3.9pp

STAA

73.4%

+17.6pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
EWTX	$3.49B	-19.9	-32.0%	0.7%
TWST	$3.07B	-40.0	-16.6%	28.8%
TXG	$2.79B	-63.7	-5.7%	15.1%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

6.5%

Steady Growth

4Q Net Income CAGR

30.3%

Profitability Improved

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:May 11, 2026

EPS:$0.24

Revenue:$331.65M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data